CY1107455T1 - Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη - Google Patents

Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη

Info

Publication number
CY1107455T1
CY1107455T1 CY20051100946T CY051100946T CY1107455T1 CY 1107455 T1 CY1107455 T1 CY 1107455T1 CY 20051100946 T CY20051100946 T CY 20051100946T CY 051100946 T CY051100946 T CY 051100946T CY 1107455 T1 CY1107455 T1 CY 1107455T1
Authority
CY
Cyprus
Prior art keywords
protection
composition
cancer cells
animal
dna
Prior art date
Application number
CY20051100946T
Other languages
Greek (el)
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Stéphanie READER
Original Assignee
Bioniche Life Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc. filed Critical Bioniche Life Sciences Inc.
Publication of CY1107455T1 publication Critical patent/CY1107455T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20051100946T 1999-04-01 2005-08-03 Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη CY1107455T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12745199P 1999-04-01 1999-04-01
EP00912310A EP1165106B8 (en) 1999-04-01 2000-03-30 Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc

Publications (1)

Publication Number Publication Date
CY1107455T1 true CY1107455T1 (el) 2012-12-19

Family

ID=22430191

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20051100946T CY1107455T1 (el) 1999-04-01 2005-08-03 Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη

Country Status (10)

Country Link
EP (1) EP1165106B8 (https=)
JP (1) JP2002541114A (https=)
AT (1) ATE296106T1 (https=)
AU (1) AU780909B2 (https=)
CA (1) CA2366090C (https=)
CY (1) CY1107455T1 (https=)
DE (1) DE60020352T2 (https=)
ES (1) ES2238996T3 (https=)
PT (1) PT1165106E (https=)
WO (1) WO2000059518A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033879A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Method for the treatment of inflammation
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
AU3413500A (en) 2000-10-23
DE60020352D1 (de) 2005-06-30
EP1165106B8 (en) 2005-07-27
WO2000059518A2 (en) 2000-10-12
JP2002541114A (ja) 2002-12-03
ATE296106T1 (de) 2005-06-15
DE60020352T2 (de) 2005-10-20
WO2000059518A3 (en) 2001-02-01
CA2366090C (en) 2011-05-24
PT1165106E (pt) 2005-10-31
EP1165106A2 (en) 2002-01-02
EP1165106B1 (en) 2005-05-25
CA2366090A1 (en) 2000-10-12
ES2238996T3 (es) 2005-09-16
AU780909B2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
ES2139904T3 (es) Sistema de suministro celular de ciclodextrina para oligonucleotidos.
KR960704582A (ko) 텍사피린을 사용하는 방사선 감작방법(Radiation sentization using texaphyrins)
ATE324888T1 (de) Krebstherapie
CY1108778T1 (el) Μεθοδος αντιμετωπισης καρκινου του δερματος, χρησιμοποιωντας συνθεσεις οι οποιες περιλαμβανουν εναν αναστολεα του υποδοχεα ενδοθηλινης β
CA2291065A1 (en) Raf kinase inhibitors
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
DE59709437D1 (de) Neue phenanthridine
CA2534816A1 (en) Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
PL374675A1 (en) Use of urease for inhibiting cancer cell growth
CY1107455T1 (el) Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DK1509523T3 (da) Triazaspiro-forbindelser anvendelige for at behandle eller forhindre smerte
PT1054680E (pt) Tratamento do cancro da bexiga pela parede celular de mycobacterium phlei
TR200102576T2 (tr) Kanser tedavisinde radyoaktif sisplatin
RU97111568A (ru) Способ лечения онкологических больных
DE69919386D1 (de) Zusammensetzung zur behandlung von entzündungen
Hill et al. Exogenous melanin and ionizing radiation are synergistic in producing strand breaks in DNA
KR870007191A (ko) 유기백금착물 및 이를 사용한 종양 치료방법
Heikkila Studies on the mode of action of 6-hydroxydopamine and related neurotoxins
IT1306187B1 (it) Metodo per l'eradicazione selettiva di cellule tumorali aventi lafunzione di p53 inattiva.
BR9706727A (pt) Tk2- produtos basicos da catacholase tratamento de tumores (câncer).
CY1114754T1 (el) Χρηση ουρεασης για αναστολη αναπτυξης καρκινικου κυτταρου